Improved glycemic control in mice lacking Sglt1 and Sglt2. - Wikidata - awgldk - TriplyDB

Improved glycemic control in mice lacking Sglt1 and Sglt2.

Improved glycemic control in mice lacking Sglt1 and Sglt2.

http://www.wikidata.org/entity/Q51349034

about

Stimulation of incretin secreting cells Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes.Sotagliflozin improves glycemic control in nonobese diabetes-prone mice with type 1 diabetes.Inhibition of kidney proximal tubular glucose reabsorption does not prevent against diabetic nephropathy in type 1 diabetic eNOS knockout mice.LP-925219 maximizes urinary glucose excretion in mice by inhibiting both renal SGLT1 and SGLT2.Diacylglycerol Lipase α Knockout Mice Demonstrate Metabolic and Behavioral Phenotypes Similar to Those of Cannabinoid Receptor 1 Knockout Mice.Novel Agents for the Treatment of Type 2 Diabetes.Amoxicillin and amoxicillin/clavulanate reduce ethanol intake and increase GLT-1 expression as well as AKT phosphorylation in mesocorticolimbic regions.SGLT inhibitors attenuate NO-dependent vascular relaxation in the pulmonary artery but not in the coronary artery.Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus SGLT2 inhibitor therapy improves blood glucose but does not prevent diabetic bone disease in diabetic DBA/2J male mice.Sodium glucose cotransporter 2 inhibition in the diabetic kidney: an update Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes.Fatty acid desaturase 1 knockout mice are lean with improved glycemic control and decreased development of atheromatous plaque.Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes Inhibition of AAK1 Kinase as a Novel Therapeutic Approach to Treat Neuropathic Pain.Greater dose-ranging effects on A1C levels than on glucosuria with LX4211, a dual inhibitor of SGLT1 and SGLT2, in patients with type 2 diabetes on metformin monotherapy SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice.Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia.SGLT2: a potential target for the pharmacogenetics of Type 2 diabetes?Emerging sodium/glucose co-transporter 2 inhibitors for type 2 diabetes.Molecular mechanisms of incretin hormone secretion.Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences.Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor.A comprehensive review of the pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and humans.Sotagliflozin as a potential treatment for type 2 diabetes mellitus.Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus.SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy.Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus.Intestinal SGLT1 in metabolic health and disease.Fingerprints of hSGLT5 sugar and cation selectivity.Dapagliflozin Binds Specifically to Sodium-Glucose Cotransporter 2 in the Proximal Renal Tubule.Use of systems pharmacology modeling to elucidate the operating characteristics of SGLT1 and SGLT2 in renal glucose reabsorption in humans Study design and rationale of a dose-ranging trial of LX4211, a dual inhibitor of SGLT1 and SGLT2, in type 2 diabetes inadequately controlled on metformin monotherapy.Revisiting the physiological roles of SGLTs and GLUTs using positron emission tomography in mice.A more tubulocentric view of diabetic kidney disease.Efficacy and safety of sotagliflozin in treating diabetes type 1.Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion.Intestinal absorption of glucose in mice as determined by positron emission tomography.

P2860

Q26765259-A52D9761-B90F-4CD2-B368-9A98F8BC009B Q33356608-A4510540-F11B-4782-8F74-41465D78AB4A Q33625568-AACD577D-8FD0-4B1A-A04A-4D6AFEF0DFE4 Q35137042-CC00198D-2B72-46D0-BA72-CC49D5CDC2BF Q35392355-4066B469-2462-4240-A527-30846BF24588 Q35664940-C101881D-EE08-4D28-9DFA-969DCD34E0D0 Q35672654-C0A01EFF-454A-450D-9B88-7978713C6AD3 Q35910421-283C3DFD-137D-4D5C-874F-4C0B51BD4DCF Q36037560-497E6F20-D8C9-44B1-B40F-74D18B595FE1 Q36237217-90EC76F7-878E-4984-A1A1-943D331858CA Q36345951-3EF2D151-1D7D-4158-8975-F1EECC16EB09 Q36372598-C2721679-9434-41CF-B2A6-8E714054A92E Q36435496-DC0A347E-2B62-4802-BDB8-18C01229BB72 Q36798680-85CEE646-756A-48A6-91CA-E0BFED2E6AAB Q37042588-6892F12D-3A8D-4CC1-89CC-3752C032A7D8 Q37193454-FEEFF694-8293-46A6-96E4-8DE11AD572CD Q37206282-3D4CF0C8-56B6-4CC9-AA8F-DCE897B8DE76 Q37461695-E10F7158-E262-4289-954C-97320853E309 Q37575455-26881160-F811-4EF1-B22D-1FD61B51AFB9 Q37575461-2C60126A-B8B5-4AEF-9E72-457E6FC04B23 Q38104746-2BE70AE9-7E43-4605-AE43-5B07C426DE01 Q38130748-FA4CC873-9C7D-4035-8872-270C418490FA Q38137525-636FD3E1-E4AA-4BA1-8DE7-6F7852629DD7 Q38330456-56FEEA57-A482-48CB-B880-8AC8F3BDDDFE Q38358921-38A6B4DB-54B9-4863-99E3-A1FE10A4DC79 Q38537119-848E2A5D-55B4-45E8-A256-80ED99331A95 Q38628037-DF3A888B-F0AD-4304-A015-7B30EECC38EA Q38638523-0C86A8E2-8F98-484D-B4DE-FB240F504985 Q38775305-97C43B51-2768-4AC7-8B16-C2E1BA9BAB37 Q38783130-88331CA0-0C31-4920-B063-D3BF4DB5BA02 Q38787917-3325B645-593B-4C5B-807D-9BEAA1B8307E Q39020680-E4A44047-4235-4A0B-BF39-6F658D26AC4D Q39398592-FBF30A84-0E7B-4733-B954-98D824C7665D Q41649918-1A6EAE04-3FBA-40DE-8C64-EF178F63A670 Q44757675-1C003E3D-8611-48AD-B5D4-212C69B8D91F Q46132953-CA999025-8141-494E-8B87-C7A897764F00 Q47108081-60A66065-AD86-4FBE-AEAD-B91D686FC553 Q50047534-13895E0F-0A3B-4DB3-966C-1F117A871510 Q51304272-8ACEBA02-AC8D-46CE-BF48-2C70C5096483 Q55514768-0211E800-FC65-43AB-913E-2F6B51569F08

P2860

Improved glycemic control in mice lacking Sglt1 and Sglt2.

http://www.wikidata.org/entity/Q51349034

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh-hant

name

Improved glycemic control in mice lacking Sglt1 and Sglt2.

@en

Improved glycemic control in mice lacking Sglt1 and Sglt2.

@nl

type

label

Improved glycemic control in mice lacking Sglt1 and Sglt2.

@en

Improved glycemic control in mice lacking Sglt1 and Sglt2.

@nl

prefLabel

Improved glycemic control in mice lacking Sglt1 and Sglt2.

@en

Improved glycemic control in mice lacking Sglt1 and Sglt2.

@nl

P1433

Q51349034-DEAE1006-0A20-4E29-A0F5-17586EEAA6DA

P1476

Q51349034-2B84A8DC-9D2B-4A50-9D2E-0678A5A74962

P2093

Q51349034-1B8D63F7-9871-45CB-9E3C-9EE83863B8B2

Q51349034-1BA33E31-DC92-4144-8C28-B2C27A382BA6

Q51349034-1E8F32F1-3DE1-4112-84FD-2A5D87DC3DC1

Q51349034-2623C3CE-765A-474C-8502-0453BACB3231

Q51349034-33F40486-6E30-4828-BA33-90024EA9BA32

Q51349034-3AD3CFF4-C847-4187-B9F4-587C40F37804

Q51349034-3E2AF095-4F40-414F-AA81-24FF9B088662

Q51349034-4D2702A5-7461-459A-9658-27B3C1E6157F

Q51349034-592CDB9A-6466-4C4C-A6D5-B410E63DBB00

Q51349034-5BF7B00E-F332-4909-B7AA-4BF369F406DD

P2860

Q51349034-002C0CA5-84F2-41DD-9036-EE11BDC3D4E5

Q51349034-02C7E751-EF21-4C49-BDA5-3CB22F3758EB

Q51349034-048C2484-3D34-4A77-B641-8AC0BE3691AA

Q51349034-0D8B5BF1-8FBD-4978-86A1-18E24BF94BD3

Q51349034-2456EA76-4764-4C52-9D93-ADBDE8D1D15B

Q51349034-2DA28667-65A1-486E-A4AF-82FEE1DB65B3

Q51349034-2E391AA3-DDD8-45A2-8064-42C17E1CA1CB

Q51349034-2EC8E3D5-9C0B-4989-A336-52C04C21ECA8

Q51349034-2F1CF65D-E003-476D-B39B-74110E1077F9

Q51349034-3D8A9121-7003-4B2A-9D28-8C16180C14AB

P304

Q51349034-37281C9A-BC80-4DC3-8B7D-599C0EC6D7F2

P31

Q51349034-90FA1C66-4091-4722-8FA1-07C1374151BB

P356

Q51349034-31193C6A-5F39-4A40-B1BF-1577771F6BFA

P433

Q51349034-51E3BFDA-95AB-47B6-8016-F45246EBEFFC

P478

Q51349034-3F3EFA95-A67B-4E2C-A871-EA0B79755F4A

P50

Q51349034-ABD46E87-A3AB-48C4-ACCF-784C231117AA

P577

Q51349034-C58F82F3-451F-484C-990C-A9D033F54098

P5875

Q51349034-113F183A-F857-4D3F-A35B-DF72F0E8F6C0

P698

Q51349034-8622B139-F70C-4199-9F86-475B108274CA

P356

AJPENDO.00439.2012

P1433

American Journal of Physiology - Endocrinology and Metabolism

P1476

Improved glycemic control in mice lacking Sglt1 and Sglt2

@en

P2093

Angela Harris

http://www.w3.org/2001/XMLSchema#string

Arthur T Sands

http://www.w3.org/2001/XMLSchema#string

Brian Zambrowicz

http://www.w3.org/2001/XMLSchema#string

Christopher M DaCosta

http://www.w3.org/2001/XMLSchema#string

David R Powell

http://www.w3.org/2001/XMLSchema#string

Deon Doree

http://www.w3.org/2001/XMLSchema#string

Faika Mseeh

http://www.w3.org/2001/XMLSchema#string

Jason Gay

http://www.w3.org/2001/XMLSchema#string

Jennifer Greer

http://www.w3.org/2001/XMLSchema#string

Kenneth A Platt

http://www.w3.org/2001/XMLSchema#string

P2860

Defects in Na+/glucose cotransporter (SGLT1) trafficking and function cause glucose-galactose malabsorption

Proteinuria and perinatal lethality in mice lacking NEPH1, a novel protein with homology to NEPHRIN

Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats

Molecular analysis of the SGLT2 gene in patients with renal glucosuria

Twenty-one additional cases of familial renal glucosuria: absence of genetic heterogeneity, high prevalence of private mutations and further evidence of volume depletion

Expression cloning and cDNA sequencing of the Na+/glucose co-transporter

Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na(+)-glucose cotransporter inhibitor T-1095

Wnk1 kinase deficiency lowers blood pressure in mice: a gene-trap screen to identify potential targets for therapeutic intervention

Disruption and sequence identification of 2,000 genes in mouse embryonic stem cells.

New drug targets for type 2 diabetes and the metabolic syndrome.

P304

E117-30

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1152/AJPENDO.00439.2012

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

304

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-11-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233411231

http://www.w3.org/2001/XMLSchema#string

P698

23149623

http://www.w3.org/2001/XMLSchema#string